Fasenra
E505485
Fasenra is a monoclonal antibody medication used to treat severe eosinophilic asthma by targeting and reducing eosinophil levels.
Statements (45)
| Predicate | Object |
|---|---|
| instanceOf |
medication
ⓘ
monoclonal antibody ⓘ |
| administrationFrequencyMaintenance | every 8 weeks ⓘ |
| administrationSetting | healthcare professional supervision ⓘ |
| antibodyType | IgG1 kappa ⓘ |
| approvalYear | 2017 ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| bindingTargetCellType |
basophils
ⓘ
eosinophils ⓘ |
| commonAdverseEffect |
headache
ⓘ
injection site reactions ⓘ pharyngitis ⓘ |
| contraindication | known hypersensitivity to benralizumab ⓘ |
| developedBy |
AstraZeneca
NERFINISHED
ⓘ
MedImmune NERFINISHED ⓘ |
| dosingRegimen |
initially every 4 weeks for the first 3 doses
ⓘ
then every 8 weeks ⓘ |
| hasATCCode | R03DX10 ⓘ |
| hasDosageForm |
autoinjector pen
ⓘ
prefilled syringe ⓘ solution for injection ⓘ |
| hasDrugClass | interleukin-5 receptor alpha antagonist ⓘ |
| hasGenericName | benralizumab ⓘ |
| improves |
asthma symptom control
ⓘ
lung function in severe eosinophilic asthma ⓘ |
| indicatedFor | add-on maintenance treatment of severe eosinophilic asthma ⓘ |
| induces | apoptosis of eosinophils via NK cell-mediated cytotoxicity ⓘ |
| isBrandNameOf | benralizumab ⓘ |
| isHumanized | true ⓘ |
| isNotIndicatedFor |
acute bronchospasm
ⓘ
status asthmaticus ⓘ |
| isPrescriptionOnly | true ⓘ |
| mechanismOfAction |
induces antibody-dependent cell-mediated cytotoxicity of eosinophils
ⓘ
reduces eosinophil levels ⓘ |
| origin | recombinant DNA technology ⓘ |
| pregnancyCategory | insufficient human data ⓘ |
| reduces |
asthma exacerbation rate
ⓘ
blood eosinophil counts ⓘ |
| routeOfAdministration | subcutaneous injection ⓘ |
| seriousAdverseEffect | hypersensitivity reactions ⓘ |
| targets | interleukin-5 receptor alpha ⓘ |
| therapeuticArea |
allergy and immunology
ⓘ
respiratory disease ⓘ |
| treats | severe eosinophilic asthma ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.